DCB Newsletter #2/26: IT’S A WRAP! A Recap of The Insulin Insight Conference 2026
DCB Newsletter #2/26: IT’S A WRAP! A Recap of The Insulin Insight Conference 2026
Dear Community,
The Insulin Insight Conference 2026 recently took place at sitem-insel AG in Bern. It brought together leading minds across the insulin ecosystem to explore pioneering science, clinical practice, and real-world challenges. Some of you could not join us, unfortunately. But no worries, we got you covered! The ultimate, unmissable roundup can be found below.
“We organized the Insulin Insight Conference to give insulin the visibility and place it deserves.”
– Maren Schinz, Beyond Diagnostics
The Biology of Insulin: Basics & Breakthroughs
José Garcia-Tirado, University of Bern and DCB, opened the conference by highlighting that real-world glycemic outcomes often fall short of targets, persistently across age groups, diabetes duration, and treatment types. Adjunctive therapies to insulin could help to achieve full metabolic control. The AID-JUNCT study, led by José and his team, is exploring this very topic: Improving glycemic control in PwT1D on adjuvant GIP/GLP-1RA alongside AIDs. For more details, contact AID-Junct@spital.so.ch
The INSPIRE Lab at DCB, Stefanie Dobitz and Danai C. Kokona, explored how real-world conditions impact the biological activity of insulin. Using cell and in vivo studies, the team was able to show how temperature and mechanical stress effect the ability of insulin to lower blood glucose levels. A sneak peak into preliminary results from anonymized, donated real-world insulin samples confirmed the negative impact of environmental stress.
The conference`s biology of insulin session concluded with Martina Rothenbühler, DCB, who discussed how premenopausal women with T1D often experience changes in blood glucose levels related to their menstrual cycle. These natural hormone fluctuations can complicate diabetes management, as current AID systems do not account for them. The TIMES study, conducted by DCB, aims to provide scientific insights into how insulin needs and blood glucose levels evolve during the menstrual cycle. For more details, contact times@dcberne.com
The Real-World Perspective
After lunch, James Elliott from VIA Diabetes energized the audience with a powerful reminder: Insulin is still out of reach for many and still too expensive for many more, leaving PwD to die needlessly. The insulin crisis is undeniably complex, but VIA Diabetes is taking action. Their approach? Putting PwD at the heart of decision-making and amplifying diabetes awareness across all relevant sectors and stakeholders. By ensuring those directly affected have a seat at the table, they pursue real, impactful change.
Jessica Zafra Tanaka, University of Geneva, engaged with the audience to take a systems view on insulin access. Systems are complex and range from research, development, and manufacturing of a medication all the way to its prescription and use. Jessica highlighted the struggles of global insulin access due to multiple barriers at global and national level. To encourage: acciss, the NCD Policy Lab, and the T1D Commission all work on addressing specific challenges – From documenting global barriers to insulin access, to pooled procurement and regulations, all the way to delivery of care and social aspects.
“The future is now.”
Christa Cepuch, Brigham and Women`s Hospital
Christa Cepuch from Brigham and Women’s Hospital shared a powerful message: innovation and access must work together. Today, standards of care vary significantly between countries and strongly depend on locally available resources. While progress is being made, we must ask: How can we create lasting, systemic change? The future of diabetes care is about fairness. Global impact must be a priority from the very beginning of research and development, not an afterthought.
This session wrapped up with a presentation from Timothy J. Garrett, University of Florida, who challenged us to rethink how we store insulin. Potency tells us how much insulin is in your pen or vial, while bioidentity shows how effectively it lowers blood glucose (i.e. its efficacy). The good news? Insulin – Whether mailed from US pharmacies, stored in clay pots, or even briefly exposed to high temperatures – keeps its potency. The catch: We measure potency, not bioidentity. Without testing how well insulin actually works in the body, we might be missing a critical piece of the puzzle.
The Future
After a re-energizing coffee break Maren Schinz from Beyond Diagnostics presented LUMIQ: A test to determine insulin efficacy at the point of care. Current solution such as temperature sensors or cooling pouches allow to monitor and maintain the temperature of insulin. However, temperature does not equal efficacy. Using LUMIQ, it is possible to determine how effective your insulin medication is in real-time, reducing treatment uncertainty – Is my medication working properly? – and improving clinical outcomes.
Last but for sure not least Ulrike Menkes from Alva Innovations highlighted the dual role of insulin preservatives. While preservatives support insulin formulation stability, they also act as potential inflammation promoters compromising insulin delivery. With their In Line Just-In-Time Insulin Infusion Filter, Alva Innovations prolongs the lifespan of pump sets and helps maintain healthy skin.
“If you do an innovation, you accept challenges, and you need to be bold.”
Ulrike Menkes, Alva Innovations
Looking Forward
At the networking reception everyone agreed: The Insulin Insight Conference 2026 was a huge success! Inspiring talks, a diverse audience, and a collaborative atmosphere made this day one to remember. Fresh scientific insights, practical knowledge, and a cross-disciplinary dialogue-built connections to shape the future of insulin management, reinforcing its essential role in diabetes care.
Let’s keep the conversation going! Share your biggest takeaway, a challenge you’re facing, or a wish for the future in the comments below. How can we turn these insights into action? What should we explore next? Looking to collaborate? Reach out to us, contact maren.schinz@dcberne.com and stefanie.dobitz@dcberne.com.
This post was previously published in Linkedin. Click here to see the original publication.
But could the same data tell us much more about a person's health than we currently realise?
A new study published in npj Digital Medicine suggests that looking beyond individual glucose readings could reveal patterns associated with diabetes-related health risks. The findings point towards an interesting possibility: CGM technology may one day help us understand glucose levels, and also identify individual risk profiles and support more personalised diabetes care.
What did the researchers discover?
The researchers analysed CGM data from 90,757 participants in the iCanNet cohort, including people with normoglycemia, prediabetes, type 1 diabetes and type 2 diabetes. Rather than looking at individual glucose values alone, they examined 48 different CGM-derived metrics, including glucose variability and patterns over time. Their analysis revealed distinct glucose patterns across the different groups. Combining several metrics also improved the researchers' ability to distinguish between them.
Particularly interesting were the findings among people living with type 2 diabetes.
The researchers identified four distinct glycemic phenotypes – different patterns of glucose levels and fluctuations – associated with varying risks of diabetes-related complications.
For example:
- Sustained high glucose levels were associated with a 59% higher relative risk of acute complications.
- High glucose variability was associated with a 75% higher relative risk of acute complications and a 41% higher relative risk of chronic complications.
The researchers also developed a Digital Glycemic Risk Score (DGRS), combining multiple CGM metrics to identify people with potentially elevated risks.
Among participants with type 2 diabetes who had already achieved a Time in Range of at least 70%, the model reclassified 25% into a high-risk category for acute complications and 22.3% into a high-risk category for chronic complications. These were classifications generated by the model, not confirmed predictions of complications occurring in these individuals.
The findings suggest that combining different glucose patterns may reveal information about health risks that commonly used CGM metrics alone do not fully capture.
From CGM data to new insights. The study analysed 48 CGM-derived metrics from 90,757 participants and identified distinct glucose patterns across the diabetes spectrum. Among people with type 2 diabetes, four glycemic phenotypes were associated with
What could this mean for diabetes care?
Today, CGM systems primarily help people understand what is happening with their glucose levels and respond accordingly. But the enormous amount of data these devices generate may hold additional information that we are only beginning to explore.
By analysing glucose patterns over time, researchers may be able to develop digital biomarkers – measurable indicators derived from digital health data – that could help characterise individual metabolic profiles and identify potential health risks.
In the future, this could support healthcare professionals in recognising people who may benefit from closer monitoring or more personalised treatment approaches.
The Nordic region remains the global hotspot for childhood‑onset T1D. Finland has historically reported the highest incidence worldwide – around 60 per 100,000 children per year – although this rate appears to have stabilised or slightly declined since the early 2000s. Sweden, Norway and Denmark follow closely, and the IDF Diabetes Atlas 11 still places Finland, Sweden and Norway among the global top ten for published incidence.
A 2024 systematic review of European paediatric data (1994–2022) confirmed that the Nordic countries retain the highest absolute incidence in Europe, even as their rate of increase has slowed relative to the rapid rise in previously low‑incidence Central and Eastern European countries. A Swedish nationwide cohort study of 2.9 million children found that the heritability of childhood‑onset T1D has remained high and stable at around 0.83 over 30 years, implying that known environmental factors explain less than 10% of the observed rise.
In France, Santé publique France reports an annual T1D incidence increase of approximately 4%. Paediatric incidence rose from 15.4 to 19.1 per 100,000 person‑years between 2010 and 2015, with an overall rate of 19.5 per 100,000 in 2015–2017 and substantial regional variation. Sardinia (Italy) now reports the world’s highest published paediatric incidence at 76.3 per 100,000 (2022), having overtaken Finland, while the United Kingdom and Ireland also remain in the global top ten.
Projections to 2050
Two major modelling efforts suggest the same direction of travel. The GBD 2021 study projects that age‑standardised global type 1 diabetes prevalence will rise by about 23.9% between 2021 and 2050, a smaller relative increase than for type 2 diabetes, but a substantial absolute rise given the lifelong management burden of T1D. The IDF Diabetes Atlas 11 projects that overall adult diabetes prevalence (type 1 and type 2) will grow from 589 million in 2024 to around 853 million by 2050, a 46% absolute increase. While most of this growth is driven by type 2 diabetes, T1D contributes meaningfully through sustained or rising incidence in high‑income countries and improved survival, which increases prevalence even if incidence stabilises.
For the U.S., a modelling exercise based on SEARCH data suggests that, under a linear‑increase scenario, the number of young people with T1D could nearly triple by 2050, with the steepest relative growth among Hispanic and Black children.
Why is incidence rising?
T1D is a polygenic autoimmune disease in which environmental triggers act on a susceptible genetic background. Several, often overlapping, hypotheses are under investigation:
- Reduced early‑life exposure to common infections (“hygiene hypothesis”), with mixed evidence.
- Rising childhood adiposity and insulin resistance, which may accelerate the clinical presentation of existing islet autoimmunity (“accelerator hypothesis”).
- Viral triggers such as enteroviruses and, more recently, SARS‑CoV‑2, where meta‑analyses report a 14–27% increase in paediatric T1D incidence during the pandemic.
- Dietary and microbiome‑related factors, including early cow’s‑milk exposure, gluten timing and shifts in the infant gut microbiome.
- Vitamin D status and latitude, endocrine‑disrupting chemicals, pollution and perinatal factors such as higher maternal age, higher birth weight and Caesarean delivery.
The Swedish cohort study mentioned above is a stark reminder of how much remains unexplained: even with population‑wide data on several environmental exposures, less than 10% of the rise in T1D incidence in Sweden could be attributed to known factors. This underscores the need for long‑term birth cohorts, population‑level islet‑autoantibody screening and mechanistic immunology.
Implications for the next decade
Three practical implications stand out for health systems, innovators and the diabetes community:
- Health systems need to prepare for more people living with type 1 diabetes. Even under conservative assumptions, the number of people living with type 1 diabetes will continue to rise. This has practical consequences for insulin and sensor supply, reimbursement for diabetes technology, specialist care and clinical-trial infrastructure.
- Early detection is becoming more relevant. Type 1 diabetes can often be detected before symptoms appear, through markers of early autoimmune activity. With the first therapy now approved to delay clinical onset in people at an early disease stage, screening is no longer only a research question. Programmes such as Fr1da in Germany and the D1Ce trial in Italy show how early identification could inform future intervention strategies.
- We still need to understand why incidence is rising. Many environmental factors are being studied, but no single explanation is sufficient. Until we better understand the drivers behind the increase, true primary prevention will remain out of reach. This makes high-quality registries, long-term cohort studies and coordinated research more important than ever.
At DCB, we see these trends as both a warning and a call to action.
The rising incidence of type 1 diabetes will require sustained collaboration between clinicians, researchers, industry, policymakers and crucially people living with diabetes and their families.
Our work in innovation, clinical research infrastructure and community engagement aims to contribute to that collective effort.
Selected sources
GBD 2021 Diabetes Collaborators. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050. The Lancet, 2023. https://www.thelancet.com/article/S0140-6736(23)01301-6/fulltext
International Diabetes Federation. IDF Diabetes Atlas, 11th edition. 2025. https://diabetesatlas.org/
Ogle GD, et al. Global type 1 diabetes prevalence, incidence, and mortality estimates 2025: Results from the IDF Atlas 11 and the T1D Index v3.0. Diabetes Research and Clinical Practice, 2025. https://www.sciencedirect.com/science/article/pii/S0168822725002918
Stahl-Pehe A, et al. Wave in Pediatric Type 1 Diabetes Incidence After the Emergence of COVID-19: Peak and Trough Patterns in German Youth — DPV Registry. Diabetes Care, 2025. https://diabetesjournals.org/care/article/48/4/e47/157803/
Buchmann M, et al. Type 1 diabetes incidence curves differ by age for girls and boys between 1996 and 2022: Results from the North Rhine-Westphalia Diabetes Registry. Diabetes Research and Clinical Practice, 2025. https://www.sciencedirect.com/science/article/pii/S0168822725000105
Nagl K, et al. Ongoing Increase in Incidence of Diabetes in Austrian Children and Adolescents 1989–2021. Pediatric Diabetes, 2023. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12017070/
Schoenle EJ, et al. Epidemiology of Type I diabetes mellitus in Switzerland: Steep rise in incidence in under-5 year old children in the past decade. Diabetologia, 2001. https://www.researchgate.net/publication/12017578
Santé publique France. Diabetes — Data. Updated 2024. https://www.santepubliquefrance.fr/en/diabete/data
Piffaretti C, et al. Trends in childhood type 1 diabetes incidence in France, 2010–2015. Diabetes Research and Clinical Practice, 2018. https://www.sciencedirect.com/science/article/abs/pii/S0168822718304662
Ruiz-Grao MC, et al. Trends in the Incidence of Type 1 Diabetes in European Children and Adolescents from 1994 to 2022: A Systematic Review and Meta-Analysis. Pediatric Diabetes, 2024. https://onlinelibrary.wiley.com/doi/10.1155/2024/2338922
Ji J, et al. Stable heritability of type 1 diabetes in a Swedish Nationwide Cohort Study. Nature Communications, 2024. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12174315/
D’Souza D, et al. Incidence of Diabetes in Children and Adolescents During the COVID-19 Pandemic: A Systematic Review and Meta-Analysis. JAMA Network Open, 2023. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10314307/
Quinn LM, et al. Environmental Determinants of Type 1 Diabetes: From Association to Proving Causality. Frontiers in Immunology, 2021. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8518604/
Esposito S, et al. Changes in the Global Epidemiology of Type 1 Diabetes in an Evolving Landscape of Environmental Factors. International Journal of Molecular Sciences, 2023. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10141720/
Rogers MAM, et al. Fluctuations in the incidence of type 1 diabetes in the United States from 2001 to 2015: a longitudinal study. BMC Medicine, 2017. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5688827/
Imperatore G, et al. Projections of Type 1 and Type 2 Diabetes Burden in the U.S. Population Aged <20 Years Through 2050. Diabetes Care, 2012. https://pmc.ncbi.nlm.nih.gov/articles/PMC3507562/
We hope this overview is helpful for your own work in diabetes care, research or advocacy. As always, we are grateful for your interest in and support of our activities and we look forward to continuing this conversation with you in future editions of our “DID YOU KNOW…” series.
An earlier version of this article was originally published in the private newsletter of our CEO, Derek Brandt here: Diabetes Technology News.
This post was previously published in Linkedin. Click here to see the original publication.
DCB Research AG
Freiburgstrasse 3
3010 Bern
Schweiz